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Nearly 4CWN patients die of congestive heart failure each 
year. Although death may result from progressive leit ven- 
tricular dysfunction or an intercurrent myocardial or we- 
bra1 ischemic event, nearly 35 to 45% of affected patients die 
suddenly, presumably as a consequence of a malirnant 
ventricular tachyarrhythmia (l-3).- Until recently, most 
phamtacnlogic approaches to the treatment of heart failure 
have been directed toward producing hemodynamic and 
symptomatic improvement, and there has been little effort 
directed at reducing sudden death. 
Whar con we do lo am&rare rke problem of sudden 
deafk in patients witk ckronic hean foikrre? Most patients 
with heart failure have complex yet asymptomatic ventricu- 
lar arrhythmias (4-W. To the extent that such ambulatory 
arrhythmias are the predecessors of subsequent lethal 
events. we might be tempted to prevent sudden death by 
treating ventricular arrhythmias when they are detected 
during an asymptomatic phase. The advantages and disad- 
vantages of treating such asymptomatic arrhythmias have 
become the focus of a lively and continuing debate. 
Prevalence of asymptomatic ventrieulnr arrhythmias in 
heart failure (Table 1). Studies using ambulatory electrocar- 
diography indicate that 7010 95% ofpatients with congestive 
heart failure secondary to ischemic heart disease or idio- 
pathic dilated cardiomyopathy have frequent and complex 
ventricular premature beats. and that 40 to 80% have non- 
sustained vkntricular tachy&+rdia. Even a 4 h ambulatory 
recording, which was used in the Veterans Administration 
Vasodilator Heart Failure Trial (V~HeFT) (14). showed that 
2.5 to 30% ofpatients \?iith mild to moderate heart failure had 
asymptomatic nonsustained venlricular tachycardia. Long- 
term follow-up studies have also shown that 20 to 65% of 
patients with chronic heart failure die suddenly. the precise 
incidence being in part related to the definition of sudden 
death utiliied in each report. Data from our own studies 
(1,151 (in which sudden death was defined as instantaneous 
deatn or death occurring during sleep) suggest that this 
devastating complication is equally distributed between pa- 
tients with ischemic heart disease and idiopathic dilated 
cardiomyopathy. Tbe frequency of sudden death is greater in 
patients with congestive heart failure than in any other 
definable group of patients with chmnic heart disease and 
appears to be synergistically determined by the density and 
complexity of ventricular arrhythmias as well as the extent 
of left ventricular dysfunction. 
Predisposing faclors to ventricular arrhytbmim in heart 
failure. Many factors appear to contribute to the occurrence 
of ventricular arrhythmias in patients with congestive heart 
failure. The fibrotic replacement of diseased or necrotic 
myocardium in this disorder may lead to the evolution of 
irritable foci and reentrant circuits. There electrophysiologic 
abnormalities may be exacerbated in individual &entsby 
concurrent mywardial bdlammation or ischemia. Mechani- 
cal factors (excessive left ventricular dilation and regional 
wall motion abnommlities) may also create unusual kmo- 
dynamic strews that may contribute importantly to the 
tmthwenesis of arrhythmias. Electrolv~e imbalances. esw- . 
&llydiuretic-induced potassium and magnesium depletion, 
are frequent in patients with congestive heart failure. Such 
deficits may interact in the presence of inotmpic agents 
(digitalis, catecholamines and phosphodiesterase inhibitors) 
to provoke malignant ectopic rhythms. These observaticms 
have led some investigators (16) to suggest that the high 
circulating levels of catecholamines (and other neumhor- 
manes) that are found in patients with heart failure co&b 
ute importantly to the occurrence of fatal arrhythmias in this 
disorder. Although high levels of plasma norepinephrbx are 
a poor prognostic finding (with respect o rota/ mortality) in 
chronic hean failure (l7), it is not clear that neurohomtonal 
activation is an important cause of sudden death in these 
patients. 
Because of tbe prevalence of ventricular arrhyihmias, 
patients with congestive heart failure are commonly treated 
with antia~hythmic drugs. Unfortunately, this therapeutic 
approach appears to he a frequenl c~luse of serious arrhytb. 
miaa in this disorder. Antiarrhythmic drugs may exacerbate 
arrhythmias in 5 to 20% of treated patients (18.19). Patients 
with chronic heart failure may be at particular risk of this 
complication, although such an association has not been 
carefully studied. Furthermore, the phamwokinetics of 
many drugs, including antiarrhythmic agents, are greatly 
modified in patients with heart failure. Because most anti. 
arrhythmic drugs have a narrow toxic/therapeutic ratio, this 
altered metabolic disposition may greatly complicate the 
safe and effective application of these agents. Finally, most 
antiarrhythmic drugs can depress left ventricular hmction; 
this appears to be particularly true of drugs such as Recainide 
and disopyramide. These pmarrhythmic and cardicdeprer 
sant effects of antiarrhythmic drugs have raised cuncerm 
that antiarrhythmic drugs may shorten survival and increase 
(rather than decrease) the occurrence of sudden death in 
patients with chronic heart failure. It is noteworthy in this 
regurd that in the V-Hem trial (20). the use of antiarrhyth- 
mic agents was an independent risk factor for shortened 
survival. However, because the use of antiarrhythmic drugs 
was nut controlled in this study, it is difficult to determine if 
this association was observed because autiarrhythmic drugs 
were prescribed tu high risk patients or because these agents 
contributed directly to the high mortality rate in this disease. 
Tbnpeuticcumiderathms. Until large. randomized trials 
are canducted to evaluate the effect of antiarrhythmic drugs 
on the survival of patients with heart failure, we do not know 
whether this therapeutic approach should be utilized to 
prevent sudden death. Such trials are the only means of 
determining whether there is a true (or only apparent) 
relation between ventricular arrhythmias and sudden death 
in this disorder 13). Such studies can be carried out in one of 
two ways. One&roach is to enroll all subsets of patients 
with chmnic heart failure. However. there is little evidence 
that the empiric application of antiarrhythmic agents is 
beneficial in these patients (I)). A second approach is to 
enroll only patients who are at high risk of sudden death. 
Unfununately. it is not clear how such high risk patients 
would be selected. Electraphysiologic testing may o&r 
sume prognostic information in patients with symptomatic 
arrhvthmias IZI). hut it seems to be of limited utility in 
pa&s with’ &mptomatic rhythm disturbances (22.231. 
oarticularlv if their heart failure is the result of idiopathic 
hilated car&myopathy (21.24). Signal-averaged elect&r. 
diogmphy and exercise testing may contribute to the assess. 
ment of risk in some patients (2% but the accuracy of there 
tests in patients without coronary artery disease has not 
been evaluated (3). Until a valid (preferably noninvasive) 
marker of sudden death risk can be identified in uatients with 
congestive heart failure, virtually all patients &th this dis- 
order must be considered to be at risk for sudden death (2). 
and hence a potential candidate for intervention trials de- 
signed to test the utility of antiarrhythmic drugs. 
Wlmr should the clinicion do about venwicular orrhyth- 
minr in poriemr with chmnic heartfailure? Some investiga- 
tors have suggested that converting enzyme inhibitors may 
reduce the frequency of sudden death in these patients. 
Although converting enzyme inhibitors prolong life in pa- 
tients with heart failure (26) and appear to reduce the 
freauencv and comrlexitv of ventricular arrhythmias 
(27181, i is not cl& that these drugs can reduce the 
occurrence of sudden death in this disorder, although much 
cmmoversy persists concerning t&s issue (29). Ifconverting 
enzyme inhibitors exert clinically important antiarrhythmic 
effects in patients with chronic heat failure, this action does 
not appear to be mediated by an inhibitory effect of these 
drugs on the sympathetic nervous system because long-term 
treatment with captopcil and enalapril may not prevent the 
progressive rise in plasma norepinephrine levels that is 
expected to iollow pmgresrion of the heart failure state (30). 
Some inve&arors hove ssggesred rhor amiodarone may 
be rhe most &live approach to the treatment of patients 
with heart failure who have serious (yet asymptomatic) 
arrhythmias. Small uncontmlled trials (25.31) have shown 
that amiodamtte therapy produces a dramatic reduction in 
the frequency and complexity of ventricular arrhythmias in 
patients with chronic heat failum Although amiudarone is 
currently reserved fw the treatment of symplomolic life 
threatening arrhythmias because of concerns about the 
drug’s predilection to pmduce serious adverse reactions, 
such toxicity appear to be dose related, and small doses of 
the drug (200 mplday. for example) may be sufficient to 
suppress the uccurence of ventiicul?.r arthythmias without 
depressingventrifularfunction (32). Amiudamne may be the 
only antiawhythmic agent currently available that (either 
alone or in combination with other agents) may prolong life 
in uatients with chmnic heart failure (31). but there are 
se&~~s euncems about administering this potentially toxic 
drug to asymptomatic patients with this disease until the 
validity of treating asymptomatic arrhythmias can be dem 
onstrdted. 
Conelusiom. Should asymptomatic ventricular arrhyth- 
miss in patients with chronic heart failure be treated with 
antiarrh$hmic drugs in an elTml to prevent sudden death? 
This question will be debated by Kanu Chattejee and Eric 
Fwstowskv in the f&wine articles. We how that this 
interaction will lead to the piatming and conduit of a large 
scale. controlled clinical trial desimted to definitively address 
this issue. 
II. Protagonist’s Viewpoint 
KANU CHATTERJEE, MB, FRCP. FACC 
The principal rationale for the use of anliarrhythmic drugs in 
patients with congestive heart failure is to prevent the 
occurrence of sudden death. Of the 2.066 deaths in natients 
with chronic heart failure reponed in long-ten burvival 
studies (I-15). 997 deaths (46%) were classified as sudden, 
although the incidence rate varied from 4 to 86% depending 
on the definition ofsudden death used. In our own series of 
